Stockreport

Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms [Seeking Alpha]

Travere Therapeutics, Inc.  (TVTX) 
PDF FY25 revenue grew 81% to $410.5M, driven by FILSPARI's 144% YoY growth and record patient starts, signaling robust commercial momentum. Profitability metrics improved [Read more]